Logo

Formycon’s Ranopto Receives Health Canada’s Approval for the Treatment of Several Retinal Diseases

Share this
Formycon

Formycon’s Ranopto Receives Health Canada’s Approval for the Treatment of Several Retinal Diseases

Shots: 

  • Formycon along with its partners Polpharma Biologics Group BV, Bioeq AG & Teva Canada have received Health Canada’s Notice of Compliance (NOC) for Ranopto (FYB201, biosimilar Lucentis) for the treatment of various retinal diseases in Canada  
  • Ranopto was developed by Bioeq (JV of Formycon & Polpharma Biologics). In mid-2021, Teva entered a strategic partnership for the exclusive commercialization of FYB201 in Canada, Europe & other selected countries 
  • Teva expects to launch Ranopto in the Canada market by Q1’24. Ranibizumab functions by inhibiting the VEGF responsible for the excessive formation of blood vessels in the retina 

Ref: FORMYCON | Image: FORMYCON

Related News:- Formycon and its License Partner Klinge Biopharma Reports the BLA Submission of FYB203 (Biosimilar, Eylea) to the EMA

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions